DK419 是一种具有口服活性的 Wnt/β-CATenin 信号通路抑制剂，IC50 为 0.19 μM。 DK419 降低 Axin2、β-CATenin、c-Myc、Cyclin D1 和 Survivin 的蛋白质水平。它还诱导 pAMPK 的产生。

DK419 is an orally active inhibitor of Wnt/β-catenin signaling, with an IC50 of 0.19 μM. DK419 decreases protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin.It also induces production of pAMPK.

DK419 inhibited the growth of CRC tumor cells in vitro and had good plasma exposure when dosed orally[1].

DK419 inhibited the growth of patient derived CRC240 tumor explants in mice dosed orally[1].

2102672-22-8

C16H8ClF6N3O

407.7

DMSO:80 mg/mL (196.22 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years